Pneumococcal polysaccharide revaccination: Immunoglobulin G seroconversion, persistence, and safety in frail, chronically ill older subjects

被引:26
|
作者
Lackner, TE
Hamilton, RG
Hill, JJ
Davey, C
Guay, DRP
机构
[1] Univ Minnesota, Inst Study Geriatr Pharmacotherapy, Coll Pharm, Minneapolis, MN 55455 USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Abbott NW Hosp, Minneapolis, MN 55407 USA
[4] Univ Minnesota, Div Biostat, Minneapolis, MN 55455 USA
关键词
aged; bacterial vaccines; Streptococcus pneumoniae;
D O I
10.1046/j.1532-5415.2003.51064.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
OBJECTIVES: To determine the 1-month postpneumococcal polysaccharide-revaccination immunoglobulin G (IgG) antibody response, its persistence at 1 year, and tolerability of revaccination in frail, chronically ill older nursing facility residents. DESIGN: Prospective study conducted between December 1998 and July 2000. SETTING: Six skilled nursing facilities in the Minneapolis-St. Paul, Minnesota, metropolitan area. PARTICIPANTS: Sixty-seven subjects aged 65 and older having received primary vaccination with pneumococcal polysaccharide vaccine (PPV) at least 5 years before enrollment. INTERVENTION: Revaccination with one dose of 23-valent PPV. MEASUREMENTS: Adverse events and concentrations of seven individual pneumococcal polysaccharide type-specific IgG antibodies (against serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) and their aggregate before and 1 and 12 months after revaccination. RESULTS: A significant increase in all individual and aggregate median antibody concentrations over baseline was observed 1 month after revaccination. However, after 1 year, the increase remained significant only for serotypes 6B and 18C and the aggregate parameter. One month after revaccination, the mean increase in antibody concentration over baseline was significantly greater than 1.4-fold for six of the seven serotypes and the aggregate. However, the increase was not significantly greater than 1.4 at 1 year for any of the serotypes or the aggregate. Minor, self-limited localized adverse reactions and systemic reactions occurred in 11.3% of the subjects. CONCLUSIONS: In frail, chronically ill older nursing facility residents, revaccination with 23-valent PPV at least 5 years after primary vaccination (whether primary vaccination occurred before or after age 65) is associated with a significant, albeit brief, immunological response for most of the serotypes tested. Revaccination was well tolerated.
引用
收藏
页码:240 / 245
页数:6
相关论文
共 7 条
  • [1] IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: Persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response
    RodriguezBarradas, MC
    Groover, JE
    Lacke, CE
    Gump, DW
    Lahart, CJ
    Pandey, JP
    Musher, DM
    JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (06): : 1347 - 1353
  • [2] Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle-Aged and Older Adults
    Musher, Daniel M.
    Manoff, Susan B.
    Liss, Charlie
    McFetridge, Richard D.
    Marchese, Rocio D.
    Bushnell, Bonnie
    Alvarez, Frances
    Painter, Carla
    Blum, Michael D.
    Silber, Jeffrey L.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (04): : 516 - 524
  • [3] Persistence of immunity to conjugate and polysaccharide pneumococcal vaccines in frail, hospitalised older adults in long-term follow up
    MacIntyre, C. Raina
    Ridda, Iman
    Trent, Mallory J.
    McIntyre, Peter
    VACCINE, 2019, 37 (35) : 5016 - 5024
  • [4] Pneumococcal polysaccharide 23-valent vaccine: Long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults
    Grabenstein, John D.
    Manoff, Susan B.
    VACCINE, 2012, 30 (30) : 4435 - 4444
  • [5] Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults
    Musher, Daniel M.
    Manoff, Susan B.
    McFetridge, Richard D.
    Liss, Charles
    Marchese, Rocio D.
    Raab, Jennifer
    Rueda, Adriana M.
    Walker, Monica L.
    Hoover, Patricia A.
    HUMAN VACCINES, 2011, 7 (09): : 919 - 928
  • [6] Antibody persistence 10 years after 1st and 2nd doses of 23-valent pneumococcal polysaccharide vaccine (PN23), and immunogenicity and safety of 2nd and 3rd doses in older adults
    Manoff, S.
    McFetride, R.
    Liss, C.
    Marchese, R.
    Rabb, J.
    Rueda, A.
    Musher, D.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E454 - E454
  • [7] Antibody Persistence 10 Years after 1st and 2nd Doses of 23-Valent Pneumococcal Polysaccharide Vaccine (PN23), and Immunogenicity and Safety of 2nd and 3rd Doses in Older Adults
    Manoff, S.
    McFetridge, R.
    Liss, C.
    Marchese, R.
    Raab, J.
    Rueda, A.
    Musher, D.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2010, 58 : 25 - 26